Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions.
Website: gilead.com



Growth: Bad revenue growth rate -3.7%, there is slowdown compared to average historical growth rates 3.8%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +41.1%

Profitability: LTM EBITDA margin is positive, +24.3%. On average the margin is decreasing unsteadily. Gross margin is high, +78.1%. In the last quarter the company did not beat the estimated EPS, -11.0%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.17 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 4.5%. Free cash flow yield 0.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 13.5% higher than minimum and 26.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.8x by EV / Sales multiple , the company can be 1.4% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.9 mln (-0.001% of cap.)

Key Financials (Download financials)

Ticker: GILD
Share price, USD:  (-2.3%)65.54
year average price 76.84  


year start price 83.55 2023-04-27

max close price 87.29 2024-01-19

min close price 66.16 2024-04-18

current price 67.08 2024-04-25
Common stocks: 1 254 309 967

Dividend Yield:  4.5%
FCF Yield LTM: 0.9%
EV / LTM EBITDA: 11.5x
EV / EBITDA annualized: 8.8x
Last revenue growth (y/y):  -3.7%
Last growth of EBITDA (y/y):  -23.4%
Historical revenue growth:  3.8%
Historical growth of EBITDA:  14.8%
EV / Sales: 2.8x
Margin (EBITDA LTM / Revenue): 24.3%
Fundamental value created in LTM:
Market Cap ($m): 84 139
Net Debt ($m): -8 428
EV (Enterprise Value): 75 711
Price to Book: 3.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-22Zacks Investment Research

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

2024-04-19Zacks Investment Research

Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know

2024-04-18Zacks Investment Research

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

2024-04-18Zacks Investment Research

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

2024-04-16Zacks Investment Research

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

2024-04-09Zacks Investment Research

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

2024-04-09InvestorPlace

3 Stocks at 52-Week Lows Poised for a Powerful Rebound

2024-04-03Zacks Investment Research

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

2024-04-02Seeking Alpha

My April Dividend Stock Buys With Yields Up To 12%

2024-03-21Seeking Alpha

Gilead Sciences Finally Starts Succeeding
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GILD GILD GILD GILD GILD GILD
reportedCurrency USD USD USD USD USD USD
cik 882 095 882 095 882 095 882 095 882 095 882 095
fillingDate 2024-02-23 2023-11-07 2023-08-04 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-02-23 16:44:27 2023-11-07 17:18:43 2023-08-04 16:06:43 2023-05-03 16:06:40 2023-02-22 16:18:52 2022-11-02 17:02:58
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 7 115M 7 050M 6 599M 6 352M 7 389M 7 042M
costOfRevenue 1 560M 1 565M 1 442M 1 401M 1 396M 1 395M
grossProfit 5 555M 5 485M 5 157M 4 951M 5 993M 5 647M
grossProfitRatio 0.781 0.778 0.781 0.779 0.811 0.802
researchAndDevelopmentExpenses 1 452M 1 457M 1 407M 1 447M 1 548M 1 149M
generalAndAdministrativeExpenses 771M 0 0 0 0 0
sellingAndMarketingExpenses 826M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1 597M 1 315M 1 849M 1 319M 2 020M 1 213M
otherExpenses 293M -72M 152M -174M -9M 0
operatingExpenses 3 049M 2 772M 3 256M 2 766M 3 568M 2 362M
costAndExpenses 4 609M 4 337M 4 698M 4 167M 4 964M 3 757M
interestIncome 252M 232M 0 0 0 0
interestExpense 252M 232M 230M 230M 227M 229M
depreciationAndAmortization 684M 18M 389M 306M 149M 797M
ebitda 3 139M 2 641M 2 054M 2 011M 2 416M 3 634M
ebitdaratio 0.441 0.375 0.311 0.317 0.327 0.516
operatingIncome 2 506M 2 623M 1 665M 1 705M 2 267M 2 837M
operatingIncomeRatio 0.352 0.372 0.252 0.268 0.307 0.403
totalOtherIncomeExpensesNet -853M -163M -84M -405M -236M -405M
incomeBeforeTax 1 653M 2 318M 1 588M 1 300M 2 031M 2 432M
incomeBeforeTaxRatio 0.232 0.329 0.241 0.205 0.275 0.345
incomeTaxExpense 236M 146M 549M 316M 398M 646M
netIncome 1 429M 2 180M 1 045M 1 010M 1 640M 1 789M
netIncomeRatio 0.201 0.309 0.158 0.159 0.222 0.254
eps 1.150 1.750 0.840 0.810 1.310 1.430
epsdiluted 1.140 1.730 0.830 0.800 1.300 1.420
weightedAverageShsOut 1 248M 1 248M 1 249M 1 248M 1 252M 1 255M
weightedAverageShsOutDil 1 256M 1 257M 1 258M 1 261M 1 264M 1 261M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GILD GILD GILD GILD GILD GILD
reportedCurrency USD USD USD USD USD USD
cik 882 095 882 095 882 095 882 095 882 095 882 095
fillingDate 2024-02-23 2023-11-07 2023-08-04 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-02-23 16:44:27 2023-11-07 17:18:43 2023-08-04 16:06:43 2023-05-03 16:06:40 2023-02-22 16:18:52 2022-11-02 17:02:58
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 6 085M 5 705M 5 704M 4 936M 5 412M 4 699M
shortTermInvestments 1 179M 1 159M 8 001M 936M 973M 961M
cashAndShortTermInvestments 8 428M 8 021M 8 001M 7 200M 7 630M 5 660M
netReceivables 4 660M 4 790M 4 229M 4 162M 4 777M 4 354M
inventory 3 366M 3 202M 3 181M 3 010M 2 820M 1 463M
otherCurrentAssets 2 374M 2 663M 1 758M 1 846M 1 774M 2 077M
totalCurrentAssets 16 454M 16 013M 15 411M 14 372M 15 227M 13 554M
propertyPlantEquipmentNet 5 317M 5 572M 5 540M 5 479M 5 475M 5 349M
goodwill 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M
intangibleAssets 26 454M 27 152M 27 750M 28 348M 28 894M 29 440M
goodwillAndIntangibleAssets 34 768M 35 466M 36 064M 36 662M 37 208M 37 754M
longTermInvestments 1 163M 1 156M 1 334M 1 327M 1 245M 1 282M
taxAssets -1 163M -1 156M -6 446M 0 0 0
otherNonCurrentAssets 5 586M 5 323M 10 434M 4 037M 4 016M 4 618M
totalNonCurrentAssets 45 671M 46 361M 46 926M 47 505M 47 944M 49 003M
otherAssets 0 -1 000 000 0 -1 000 000 0 0
totalAssets 62 125M 62 373M 62 337M 61 876M 63 171M 62 557M
accountPayables 550M 586M 622M 627M 905M 614M
shortTermDebt 1 798M 1 793M 4 037M 2 283M 2 273M 2 270M
taxPayables 1 208M 2 088M 2 610M 3 775M 959M 902M
deferredRevenue -2 348M 2 088M -4 659M 0 0 0
otherCurrentLiabilities 11 280M 7 478M 13 964M 7 618M 8 059M 7 539M
totalCurrentLiabilities 11 280M 11 945M 13 964M 10 528M 11 237M 10 423M
longTermDebt 23 189M 24 113M 22 563M 24 233M 22 957M 22 953M
deferredRevenueNonCurrent -24 777M 72M 64M 0 0 0
deferredTaxLiabilitiesNonCurrent 1 588M 1 984M 2 106M 2 401M 2 673M 3 036M
otherNonCurrentLiabilities 28 096M 2 017M 2 546M 3 775M 5 095M 28 193M
totalNonCurrentLiabilities 28 096M 28 186M 27 279M 30 409M 30 725M 31 077M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 546M 924M 1 354M 1 277M 1 179M 0
totalLiabilities 39 376M 40 131M 41 243M 40 937M 41 962M 41 500M
preferredStock 0 0 0 0 0 0
commonStock 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000
retainedEarnings 16 304M 16 002M 15 138M 15 223M 15 687M 15 756M
accumulatedOtherComprehensiveIncomeLoss 28M 31M 10M -20M 2M 98M
othertotalStockholdersEquity 6 416M 6 208M 5 945M 5 735M 5 519M 5 226M
totalStockholdersEquity 22 749M 22 242M 21 094M 20 939M 21 209M 21 081M
totalEquity 22 665M 22 170M 21 030M 20 881M 21 209M 21 081M
totalLiabilitiesAndStockholdersEquity 62 125M 62 373M 62 337M 61 876M 63 140M 62 557M
minorityInterest -84M -72M -64M -58M -31M 0
totalLiabilitiesAndTotalEquity 62 125M 62 373M 62 337M 61 876M 63 140M 62 557M
totalInvestments 2 343M 2 315M 8 001M 2 263M 2 218M 2 243M
totalDebt 24 987M 25 906M 26 600M 26 516M 25 230M 25 223M
netDebt 18 902M 20 201M 20 896M 21 580M 19 818M 20 524M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GILD GILD GILD GILD GILD GILD
reportedCurrency USD USD USD USD USD USD
cik 882 095 882 095 882 095 882 095 882 095 882 095
fillingDate 2024-02-23 2023-11-07 2023-08-04 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-02-23 16:44:27 2023-11-07 17:18:43 2023-08-04 16:06:43 2023-05-03 16:06:40 2023-02-22 16:18:52 2022-11-02 17:02:58
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1 417M 2 172M 1 039M 985M 1 633M 1 786M
depreciationAndAmortization 688M 684M 681M 94M 528M 525M
deferredIncomeTax -370M -68M -221M -303M -338M -270M
stockBasedCompensation 201M 202M 198M 165M 174M 168M
changeInWorkingCapital -543M -1 549M 331M 136M 117M -117M
accountsReceivables 220M -612M -86M 635M -281M -372M
inventory -307M -82M -226M -227M -276M -95M
accountsPayables -43M -29M -3M -272M 264M 66M
otherWorkingCapital -413M -826M 646M -136M 410M 284M
otherNonCashItems 776M 315M 309M 667M 452M 771M
netCashProvidedByOperatingActivities 2 169M 1 756M 2 337M 1 744M 2 566M 2 863M
investmentsInPropertyPlantAndEquipment -215M -122M -139M -109M -181M -157M
acquisitionsNet -279M -79M -243M -551M -218M -448M
purchasesOfInvestments -680M -395M -645M -527M -378M -430M
salesMaturitiesOfInvestments 447M 361M 545M 491M 400M 324M
otherInvestingActivites -233M 6M -1 000 000 -130M 3M -2M
netCashUsedForInvestingActivites -727M -229M -483M -826M -374M -713M
debtRepayment -1 000 000 -2 250M -1 068M 0 -1 500M -1 000M
commonStockIssued 26M 83M 26M 97M 176M 36M
commonStockRepurchased -150M -300M -150M -400M -792M -180M
dividendsPaid -943M -953M -944M -969M -915M -929M
otherFinancingActivites -31M 1 902M 1 035M -134M 1 477M -45M
netCashUsedProvidedByFinancingActivities -1 099M -1 518M -1 101M -1 406M -1 554M -2 118M
effectOfForexChangesOnCash 37M -7M 14M 13M 75M -72M
netChangeInCash 380M 1 000 000 768M -476M 713M -40M
cashAtEndOfPeriod 6 085M 5 705M 5 704M 4 936M 5 412M 4 699M
cashAtBeginningOfPeriod 5 705M 5 704M 4 936M 5 412M 4 699M 4 739M
operatingCashFlow 2 169M 1 756M 2 337M 1 744M 2 566M 2 863M
capitalExpenditure -215M -122M -139M -109M -181M -157M
freeCashFlow 1 954M 1 634M 2 198M 1 635M 2 385M 2 706M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-08 20:05 ET
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
2024-03-28 12:30 ET
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
2024-03-22 13:18 ET
Gilead Sciences Announces Completion of Acquisition of CymaBay
2024-03-18 23:29 ET
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
2024-03-11 12:24 ET
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
2024-03-06 15:25 ET
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
2024-03-06 13:00 ET
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
2024-03-05 21:35 ET
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
2024-03-05 21:30 ET
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
2024-02-27 15:00 ET
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
2024-02-26 21:05 ET
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
2024-02-26 13:30 ET
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
2024-02-20 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2024-02-12 13:30 ET
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
2024-02-09 16:00 ET
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
2024-02-06 21:05 ET
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
2024-02-06 21:02 ET
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-01 21:31 ET
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
2024-01-30 13:30 ET
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
2024-01-23 21:05 ET
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
2024-01-22 13:30 ET
Gilead Provides Update on Phase 3 EVOKE-01 Study
2023-12-21 21:05 ET
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
2023-12-21 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conference
2023-12-12 02:00 ET
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
2023-12-12 00:30 ET
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
2023-12-11 22:45 ET
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
2023-12-11 17:00 ET
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
2023-11-30 13:30 ET
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
2023-11-09 00:13 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2023-11-07 21:02 ET
Gilead Sciences Announces Third Quarter 2023 Financial Results
2023-11-03 15:00 ET
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
2023-11-02 13:15 ET
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
2023-10-31 11:30 ET
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
2023-10-24 16:00 ET
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
2023-10-20 09:10 ET
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
2023-10-19 07:00 ET
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
2023-10-18 07:00 ET
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
2023-10-16 11:30 ET
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
2023-10-16 05:01 ET
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
2023-10-12 20:05 ET
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
2023-10-03 12:30 ET
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
2023-10-02 13:00 ET
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
2023-09-19 12:30 ET
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
2023-09-18 08:00 ET
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
2023-09-10 07:01 ET
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
2023-09-08 00:55 ET
Gilead Prices $2 Billion of Senior Unsecured Notes
2023-08-24 12:30 ET
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
2023-08-23 20:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2023-08-21 12:30 ET
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
2023-08-18 16:00 ET
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
2023-08-15 12:30 ET
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
2023-08-03 20:02 ET
Gilead Sciences Announces Second Quarter 2023 Financial Results
2023-07-27 17:23 ET
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
2023-07-24 23:00 ET
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
2023-07-24 01:51 ET
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
2023-07-23 21:00 ET
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
2023-07-21 21:02 ET
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
2023-07-20 16:00 ET
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
2023-07-20 16:00 ET
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
2023-07-20 16:00 ET
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
2023-07-19 12:30 ET
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
2023-07-14 20:05 ET
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
2023-07-14 12:00 ET
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
2023-07-13 10:00 ET
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
2023-06-23 12:11 ET
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
2023-06-23 06:30 ET
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
2023-06-22 12:30 ET
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
2023-06-14 07:00 ET
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
2023-06-07 10:00 ET
AbTherx Announces License Agreement with Gilead
2023-06-06 14:45 ET
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
2023-06-05 16:30 ET
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
2023-06-05 15:25 ET
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
2023-06-01 12:34 ET
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
2023-05-26 05:00 ET
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
2023-05-25 20:05 ET
Gilead Sciences to Present at Upcoming Investor Conference
2023-05-17 12:30 ET
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
2023-05-16 20:01 ET
Gilead Appoints Cindy Perettie Executive Vice President of Kite
2023-05-09 12:30 ET
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
2023-05-04 11:00 ET
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
2023-05-01 20:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2023-04-27 20:02 ET
Gilead Sciences Announces First Quarter 2023 Financial Results
2023-04-16 08:00 ET
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
2023-04-13 20:05 ET
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
2023-03-23 10:30 ET
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
2023-03-22 16:00 ET
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
2023-03-21 13:37 ET
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
2023-03-20 12:30 ET
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
2023-03-20 12:30 ET
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
2023-02-22 16:21 ET
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
2023-02-22 14:00 ET
Kite Completes Acquisition of Tmunity
2023-02-21 22:30 ET
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
2023-02-21 20:01 ET
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
2023-02-17 14:00 ET
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
2023-02-14 13:45 ET
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
2023-02-09 12:15 ET
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
2023-02-03 15:29 ET
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
2023-02-02 21:05 ET
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
2023-02-02 21:01 ET
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
2023-02-01 13:35 ET
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
2023-01-27 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2023-01-19 21:05 ET
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
2023-01-03 13:30 ET
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
2023-01-03 13:30 ET
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
2022-12-27 21:30 ET
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
2022-12-27 21:30 ET
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
2022-12-23 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conference
2022-12-22 21:30 ET
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
2022-12-22 15:27 ET
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
2022-12-20 13:00 ET
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
2022-12-12 16:00 ET
Gilead Sciences Again Named to Dow Jones Sustainability World Index
2022-12-12 15:00 ET
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
2022-12-12 15:00 ET
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
2022-12-11 22:30 ET
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
2022-12-11 15:00 ET
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
2022-12-07 21:30 ET
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
2022-12-06 20:00 ET
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
2022-11-29 13:30 ET
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
2022-11-29 13:00 ET
Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors
2022-11-15 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2022-11-10 15:05 ET
Gilead Sciences: A Career Rooted in Championing Diversity and Inclusion: Jesse's Story
2022-11-03 13:15 ET
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
2022-11-02 12:55 ET
Gilead's Path to Equitable Global COVID-19 Treatment Access
2022-11-02 12:00 ET
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
2022-11-02 11:01 ET
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
2022-11-01 13:00 ET
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
2022-10-27 20:01 ET
Gilead Sciences Announces Third Quarter 2022 Financial Results
2022-10-26 13:00 ET
Gilead Sciences: Metastatic Breast Cancer Advocate Urges Black People to Join Clinical Trials
2022-10-24 06:00 ET
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
2022-10-20 13:00 ET
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
2022-10-18 12:30 ET
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
2022-10-17 20:30 ET
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
2022-10-13 20:05 ET
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022
2022-10-11 12:30 ET
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
2022-10-03 13:00 ET
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
2022-09-22 12:30 ET
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
2022-09-20 20:30 ET
Gilead Sciences Completes Acquisition of MiroBio
2022-09-16 11:00 ET
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
2022-09-16 10:39 ET
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
2022-09-15 22:21 ET
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
2022-09-13 15:28 ET
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
2022-09-07 22:05 ET
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
2022-09-06 22:30 ET
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
2022-09-04 22:05 ET
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
2022-08-29 20:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2022-08-29 12:30 ET
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
2022-08-22 05:00 ET
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
2022-08-17 15:00 ET
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
2022-08-15 23:15 ET
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
2022-08-15 23:15 ET
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
2022-08-15 12:30 ET
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
2022-08-09 14:00 ET
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
2022-08-04 12:00 ET
Gilead Sciences to Acquire MiroBio
2022-08-02 20:01 ET
Gilead Sciences Announces Second Quarter 2022 Financial Results
2022-07-28 17:30 ET
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
2022-07-22 13:42 ET
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
2022-07-22 11:06 ET
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
2022-07-21 12:30 ET
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
2022-07-20 16:30 ET
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
2022-07-19 13:00 ET
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
2022-07-12 20:05 ET
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
2022-07-12 12:30 ET
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
2022-06-28 10:00 ET
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
2022-06-27 20:30 ET
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
2022-06-27 13:00 ET
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
2022-06-24 12:00 ET
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
2022-06-23 12:30 ET
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
2022-06-21 13:00 ET
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
2022-06-06 13:00 ET
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
2022-06-04 20:00 ET
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
2022-06-04 13:00 ET
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)
2022-06-04 12:30 ET
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
2022-06-04 12:00 ET
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
2022-06-03 20:00 ET
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
2022-06-02 13:00 ET
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
2022-05-19 17:30 ET
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
2022-05-17 20:30 ET
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
2022-05-16 20:10 ET
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
2022-05-02 12:30 ET
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
2022-04-28 20:02 ET
Gilead Sciences Announces First Quarter 2022 Financial Results
2022-04-26 22:13 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2022-04-25 18:29 ET
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
2022-04-24 22:05 ET
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
2022-04-19 12:00 ET
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
2022-04-14 20:05 ET
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
2022-04-11 20:07 ET
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
2022-04-01 22:01 ET
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
2022-03-28 15:00 ET
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
2022-03-07 13:30 ET
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
2022-03-01 13:30 ET
Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues
2022-02-16 18:55 ET
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
2022-02-11 22:15 ET
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
2022-02-11 22:00 ET
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
2022-02-11 13:01 ET
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
2022-02-08 13:30 ET
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
2022-02-03 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2022-02-01 21:10 ET
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
2022-02-01 21:02 ET
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
2022-01-31 14:00 ET
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
2022-01-25 23:52 ET
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
2022-01-21 23:24 ET
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
2022-01-18 21:05 ET
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
2022-01-10 13:30 ET
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
2021-12-22 22:08 ET
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
2021-12-22 00:12 ET
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
2021-12-21 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conference
2021-12-21 09:00 ET
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
2021-12-16 23:00 ET
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
2021-12-14 12:30 ET
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors
2021-12-13 19:45 ET
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
2021-12-11 15:00 ET
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
2021-12-11 14:00 ET
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
2021-12-11 13:30 ET
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
2021-12-10 13:00 ET
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
2021-11-29 14:00 ET
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients
2021-11-29 13:30 ET
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
2021-11-23 13:30 ET
Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
2021-11-19 13:00 ET
Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
2021-11-18 21:05 ET
Gilead Sciences to Present at Upcoming Investor Conference
2021-11-11 00:05 ET
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
2021-11-11 00:00 ET
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
2021-11-09 15:00 ET
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
2021-11-04 13:23 ET
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
2021-10-29 11:30 ET
Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
2021-10-28 20:10 ET
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
2021-10-28 20:02 ET
Gilead Sciences Announces Third Quarter 2021 Financial Results
2021-10-21 11:37 ET
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
2021-10-19 12:30 ET
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
2021-10-18 11:30 ET
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
2021-10-15 12:00 ET
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
2021-10-14 20:05 ET
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
2021-10-01 21:46 ET
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
2021-09-30 20:50 ET
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
2021-09-27 20:35 ET
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization
2021-09-22 13:01 ET
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
2021-09-20 12:30 ET
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
2021-09-16 11:00 ET
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
2021-09-16 11:00 ET
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
2021-09-13 12:30 ET
Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy
2021-09-01 20:05 ET
Gilead Sciences to Present at Upcoming Investor Conference
2021-08-19 20:15 ET
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
2021-08-11 12:51 ET
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
2021-08-06 19:45 ET
CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services
2021-08-06 18:51 ET
Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services
2021-08-05 12:30 ET
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
2021-08-03 14:45 ET
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
2021-07-29 20:01 ET
Gilead Sciences Announces Second Quarter 2021 Financial Results
2021-07-17 10:01 ET
Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults
2021-07-17 10:01 ET
New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor
2021-07-15 20:05 ET
Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021
2021-07-12 11:30 ET
Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research
2021-06-28 20:09 ET
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
2021-06-28 12:30 ET
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
2021-06-24 13:00 ET
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
2021-06-23 12:40 ET
Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China
2021-06-21 12:00 ET
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
2021-06-21 08:00 ET
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
2021-06-17 13:00 ET
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
2021-06-15 12:00 ET
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
2021-06-12 14:00 ET
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
2021-06-10 21:00 ET
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
2021-06-04 18:30 ET
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
2021-06-04 13:00 ET
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
2021-05-26 10:00 ET
Satcher Health Leadership Institute At Morehouse School Of Medicine, With Support From Google.org And Gilead Sciences, Launches Health Equity Tracker To Study Racial Health Inequities Related To Covid-19
2021-05-19 21:00 ET
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021
2021-05-14 20:05 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2021-05-06 20:09 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2021-04-29 20:02 ET
Gilead Sciences Announces Second Quarter 2021 Dividend
2021-04-29 20:01 ET
Gilead Sciences Announces First Quarter 2021 Financial Results
2021-04-26 22:34 ET
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India
2021-04-15 20:05 ET
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021
2021-04-14 13:25 ET
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer
2021-04-13 21:42 ET
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
2021-04-09 00:10 ET
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
2021-04-07 23:53 ET
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
2021-04-06 05:01 ET
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
2021-04-01 20:15 ET
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
2021-03-31 04:26 ET
Gilead Sciences Comments on the Passing of John C. Martin, PhD
2021-03-26 12:30 ET
Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research
2021-03-25 20:01 ET
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
2021-03-18 09:00 ET
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
2021-03-09 18:22 ET
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
2021-03-06 12:01 ET
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
2021-03-06 00:49 ET
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
2021-03-04 13:39 ET
Gilead Sciences Completes Acquisition of MYR GmbH
2021-03-02 22:21 ET
 Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
2021-02-18 13:01 ET
Gilead Sciences to Present at Upcoming Investor Conferences
2021-02-16 15:30 ET
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
2021-02-10 22:15 ET
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
2021-02-08 13:00 ET
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
2021-02-04 21:02 ET
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend
2021-02-04 21:01 ET
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
2021-02-02 13:00 ET
Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice
2021-01-21 21:01 ET
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
2021-01-19 13:00 ET
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
2021-01-11 11:00 ET
Gilead Sciences Announces Updated 2020 Guidance
2021-01-06 13:00 ET
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
2020-12-21 21:01 ET
Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
2020-12-16 08:01 ET
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
2020-12-10 21:48 ET
Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
2020-12-10 14:20 ET
Gilead Sciences to Acquire MYR GmbH
2020-12-10 13:00 ET
Gilead Sciences to Acquire MYR GmbH
2020-12-09 16:00 ET
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
2020-12-08 21:05 ET
Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
2020-12-07 11:35 ET
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
2020-12-06 20:00 ET
Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
2020-12-06 17:30 ET
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
2020-12-05 17:30 ET
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
2020-12-05 15:00 ET
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
2020-12-05 15:00 ET
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma
2020-11-24 00:00 ET
Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020
2020-11-18 13:35 ET
Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
2020-11-15 22:30 ET
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
2020-11-05 14:00 ET
Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020
2020-11-05 11:20 ET
ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to Gilead Sciences
2020-10-28 20:02 ET
Gilead Sciences Announces Fourth Quarter 2020 Dividend
2020-10-28 20:01 ET
Gilead Sciences Announces Third Quarter 2020 Financial Results
2020-10-23 13:15 ET
Gilead Sciences Completes Acquisition of Immunomedics, Inc.
2020-10-22 20:02 ET
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
2020-10-22 16:15 ET
Anthony Welters Joins Gilead Sciences’ Board of Directors
2020-10-21 11:01 ET
Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans
2020-10-19 12:30 ET
Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020
2020-10-16 11:28 ET
European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
2020-10-14 20:01 ET
Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020
2020-10-14 12:30 ET
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer
2020-10-08 21:05 ET
Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19
2020-10-08 07:00 ET
Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)
2020-10-05 10:00 ET
Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020
2020-10-01 18:00 ET
Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States
2020-09-30 12:37 ET
Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020
2020-09-25 06:00 ET
Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis
2020-09-24 02:33 ET
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes
2020-09-15 12:00 ET
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
2020-09-13 19:00 ET
Gilead Sciences to Acquire Immunomedics
2020-09-04 12:30 ET
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
2020-09-03 12:00 ET
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
2020-09-01 12:30 ET
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
2020-09-01 12:30 ET
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
2020-08-28 20:45 ET
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
2020-08-25 06:00 ET
Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress™ 2020
2020-08-18 23:25 ET
Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
2020-08-17 20:05 ET
Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration
2020-08-11 12:11 ET
China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
2020-08-10 15:00 ET
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
2020-07-30 20:02 ET
Gilead Sciences Announces Third Quarter 2020 Dividend
2020-07-30 20:01 ET
Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results
2020-07-28 13:00 ET
Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19
2020-07-24 17:25 ET
U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma
2020-07-21 12:30 ET
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million
2020-07-16 20:01 ET
Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020
2020-07-10 12:30 ET
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
2020-07-08 08:01 ET
Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders
2020-07-04 07:01 ET
New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults
2020-07-04 07:01 ET
Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)
2020-07-03 11:56 ET
European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19
2020-07-01 12:30 ET
Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual
2020-06-29 11:00 ET
An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
2020-06-23 12:30 ET
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
2020-06-16 20:05 ET
Javier Rodriguez Joins Gilead Sciences’ Board of Directors
2020-06-05 20:01 ET
New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis
2020-06-04 05:29 ET
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
2020-06-01 20:05 ET
Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs
2020-06-01 12:30 ET
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
2020-05-29 12:00 ET
Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia
2020-05-27 11:11 ET
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
2020-05-20 20:03 ET
Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis
2020-05-13 21:00 ET
Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting
2020-05-07 15:45 ET
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
2020-05-01 20:19 ET
Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19
2020-04-30 20:02 ET
Gilead Sciences Announces Second Quarter 2020 Dividend
2020-04-30 20:01 ET
Gilead Sciences Announces First Quarter 2020 Financial Results
2020-04-29 12:35 ET
Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
2020-04-29 12:30 ET
Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19
2020-04-21 20:15 ET
Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells
2020-04-16 21:30 ET
Gilead Sciences to Release First Quarter 2020 Financial Results on Thursday, April 30, 2020
2020-04-15 20:15 ET
Gilead Provides Additional Information Regarding 2020 Annual Meeting of Stockholders Due to COVID-19 Precautions
2020-04-10 19:31 ET
Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine
2020-04-08 17:09 ET
Gilead Announces $20 Million Philanthropic Fund to Support Nonprofit Organizations Impacted by the COVID-19 Crisis
2020-04-07 12:32 ET
Gilead Completes Acquisition of Forty Seven, Inc.
2020-04-06 10:15 ET
Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery
2020-03-19 18:40 ET
U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
2020-03-11 19:09 ET
New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
2020-03-10 18:33 ET
Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study
2020-03-10 15:32 ET
Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations
2020-03-09 18:53 ET
New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults
2020-03-02 11:55 ET
Gilead to Acquire Forty Seven for $4.9 Billion
2020-02-26 22:00 ET
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
2020-02-19 13:30 ET
Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company’s External Innovation Center
2020-02-19 01:00 ET
Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020
2020-02-04 21:02 ET
Gilead Sciences Announces 8 Percent Increase In First Quarter 2020 Dividend
2020-02-04 21:01 ET
Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results
2020-01-30 21:05 ET
Sandra Horning, MD, Joins Gilead Sciences’ Board of Directors
2020-01-21 22:30 ET
Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020
2020-01-13 10:45 ET
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
2020-01-09 13:30 ET
Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
2019-12-24 06:00 ET
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
2019-12-23 13:01 ET
Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
2019-12-20 13:30 ET
China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment
2019-12-19 21:30 ET
Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment
2019-12-16 13:00 ET
 Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
2019-11-27 19:16 ET
National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco
2019-11-09 21:30 ET
New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile
2019-11-08 13:00 ET
Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019
2019-11-08 13:00 ET
Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019
2019-11-08 13:00 ET
Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
2019-11-06 11:45 ET
Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials
2019-11-06 11:45 ET
Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®
2019-10-31 20:01 ET
Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
2019-10-28 12:00 ET
Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
2019-10-24 20:02 ET
Gilead Sciences Announces Fourth Quarter 2019 Dividend
2019-10-24 20:01 ET
Gilead Sciences Announces Third Quarter 2019 Financial Results
2019-10-15 12:30 ET
Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer
2019-10-10 22:00 ET
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis
2019-10-10 20:05 ET
Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019
2019-10-08 06:00 ET
Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan
2019-10-07 12:30 ET
Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
2019-10-04 12:30 ET
Gilead Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019
2019-10-03 18:49 ET
U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)
2019-04-18 20:05 ET
Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019
2019-04-16 11:00 ET
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
2019-04-11 13:18 ET
Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019
2019-04-05 12:30 ET
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
2019-03-07 22:30 ET
Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
2019-03-06 22:30 ET
Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women
2019-03-06 22:30 ET
Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance

SEC forms

Show financial reports only

SEC form 10
2024-02-23 00:00 ET
Gilead Sciences published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Gilead Sciences published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Gilead Sciences published news for 2023 q4
SEC form 10
2023-11-07 17:18 ET
Gilead Sciences published news for 2023 q3
SEC form 8
2023-11-07 16:03 ET
Gilead Sciences reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Gilead Sciences published news for 2023 q3
SEC form 10
2023-08-04 16:06 ET
Gilead Sciences published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Gilead Sciences published news for 2023 q2
SEC form 6
2023-08-03 16:07 ET
Gilead Sciences reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Gilead Sciences published news for 2023 q2
SEC form 10
2023-05-03 00:00 ET
Gilead Sciences published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Gilead Sciences published news for 2023 q1
SEC form 10
2023-02-22 16:18 ET
Gilead Sciences reported for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Gilead Sciences reported for 2022 q4
SEC form 6
2023-02-06 16:06 ET
Gilead Sciences published news for 2022 q4
SEC form 6
2023-02-02 16:03 ET
Gilead Sciences published news for 2022 q4
SEC form 8
2023-02-02 00:00 ET
Gilead Sciences reported for 2022 q4
SEC form 10
2022-11-02 17:02 ET
Gilead Sciences reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
Gilead Sciences reported for 2022 q3
SEC form 6
2022-10-27 16:04 ET
Gilead Sciences published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Gilead Sciences reported for 2022 q3
SEC form 6
2022-09-12 08:00 ET
Gilead Sciences published news for 2022 q2
SEC form 10
2022-08-08 16:43 ET
Gilead Sciences reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
Gilead Sciences reported for 2022 q2
SEC form 6
2022-08-02 16:05 ET
Gilead Sciences published news for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Gilead Sciences reported for 2022 q2
SEC form 6
2022-07-28 16:01 ET
Gilead Sciences published news for 2022 q2
SEC form 6
2022-05-31 16:01 ET
Gilead Sciences published news for 2022 q1
SEC form 6
2022-05-05 16:01 ET
Gilead Sciences published news for 2022 q1
SEC form 10
2022-05-04 16:26 ET
Gilead Sciences reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Gilead Sciences reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
Gilead Sciences published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Gilead Sciences reported for 2022 q1
SEC form 6
2022-03-24 16:03 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-03-07 08:30 ET
Gilead Sciences published news for 2021 q4
SEC form 10
2022-02-23 16:55 ET
Gilead Sciences published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-02-01 16:07 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-02-01 16:03 ET
Gilead Sciences published news for 2021 q4
SEC form 8
2022-02-01 00:00 ET
Gilead Sciences published news for 2021 q4
SEC form 8
2022-02-01 00:00 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-01-06 16:30 ET
Gilead Sciences published news for 2021 q4
SEC form 10
2021-11-03 16:30 ET
Gilead Sciences published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Gilead Sciences published news for 2021 q3
SEC form 6
2021-10-28 16:09 ET
Gilead Sciences published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Gilead Sciences published news for 2021 q3
SEC form 10
2021-08-05 16:09 ET
Gilead Sciences published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Gilead Sciences published news for 2021 q2
SEC form 6
2021-07-29 16:05 ET
Gilead Sciences published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Gilead Sciences published news for 2021 q2
SEC form 6
2021-05-14 15:04 ET
Gilead Sciences published news for 2021 q1
SEC form 10
2021-05-06 16:11 ET
Gilead Sciences published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Gilead Sciences published news for 2021 q1
SEC form 6
2021-04-29 16:06 ET
Gilead Sciences published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Gilead Sciences published news for 2021 q1
SEC form 6
2021-03-30 16:39 ET
Gilead Sciences published news for 2020 q4
SEC form 10
2021-02-25 16:15 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2021-02-04 16:05 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2021-01-11 06:04 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2021-01-06 17:25 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2020-12-08 16:14 ET
Gilead Sciences published news for 2020 q3
SEC form 10
2020-11-03 19:12 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-10-28 16:09 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-10-23 17:12 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-10-22 12:34 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-09-30 08:19 ET
Gilead Sciences published news for 2020 q2